No Data
Artiva Biotherapeutics Reports Q3 2024 Financial Results
Express News | Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Artiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial Stability
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy From TD Cowen
Express News | Artiva Biotherapeutics Q3 EPS $(0.92) Misses $(0.91) Estimate
Artiva Biotherapeutics | 8-K: Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
No Data
Wins333 : when were you in? when it was falling or rising?